|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
Maintaining Financial Stability and Reducing Cash Burn in the Biotech Sector: Financing Strategies to Foster Growth and Survive in a Challenging Market. | ||||||||||||||||
October 03, 2002 | ||||||||||||||||
Marcus Evans, Central London 2003-2-27 Among the issues to be discussed will be: Market Conditions Strategies to extend your cash life Sources of funding Surviving a downturn: SCENARIO CASE STUDIES Transparency and its effect on market confidence |
||||||||||||||||
Organized by: | Marcus Evans | |||||||||||||||
Invited Speakers: | Glen Sato, Chief Financial Officer: EXELIXIS Stephan Wehselau, Chief Financial Officer: XANTOS BIOMEDICINE AG Christine Soden, Chief Financial Officer: OXAGEN Spiro Rombotis, Chief Executive Officer: CYCLACEL LIMITED Maikel Raghoebar, Chief Development Officer: SEMAIA PHARMACEUTICALS Dr. Jane Fisken, Managing Director, Head of Global Life Sciences: DRESDNER KLEINWORT CAPITAL Susan Lowther, Chief Financial Officer: RIBOTARGETS Barry Riley, Chief Financial Officer: PROTHERICS Jonathan Pockson, Chief Financial Officer: MICROSCIENCE Leonard Brooks, Group Head, Private Equity Placement Group: UBS WARBURG Andrew Skinner, Relationship Director , Technology, Media & Telecoms: BARCLAYS CORPORATE BANKING Martin Wales, Director, European Biotech: UBS WARBURG Michael Kilpatrick, Chairman: CAMBRIDGE BIOTECHNOLOGY LTD |
|||||||||||||||
Deadline for Abstracts: | 2003-1-10 | |||||||||||||||
Registration: | For Full programme Contact: Jacquie Muhati Senior Marketing Manager Tel: +44 020 7647 2304 jacquelynem@marcusevansuk.com |
|||||||||||||||
E-mail: | jacquelynem@marcusevansuk.com | |||||||||||||||
Posted by: | Jacquie Muhati | |||||||||||||||
Host: | 194.74.216.2 | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |